| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
39,940,000 |
| Market
Cap: |
45.93(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.15 - $1.15 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Larimar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for patients suffering from rare diseases using its cell penetrating peptide technology platform. Co.'s lead product candidate, CTI-1601, is a biologic fusion protein that is administered subcutaneously, consists of a cell penetrating peptide (CPP) genetically fused to human frataxin (FXN), and includes a mitochondrial targeting sequence. Using its proprietary peptide delivery technology, CTI-1601 carries the molecule from the intravascular space across the cell membrane and into the mitochondria where the CPP and the mitochondrial targeting sequence are cleaved off to yield mature FXN.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
4,292,617 |
4,297,617 |
4,310,367 |
15,802,427 |
| Total Buy Value |
$37,521,993 |
$37,540,655 |
$37,588,070 |
$73,788,059 |
| Total People Bought |
2 |
3 |
6 |
8 |
| Total Buy Transactions |
2 |
3 |
6 |
10 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Deerfield Partners, Lp |
* Director by Deputization |
– • • |
2024-02-16 |
4 |
B |
$8.74 |
$37,499,993 |
I/I |
4,290,617 |
4,207,982 |
2.25 |
- |
|
| Thomas Frank E |
Director |
– • – |
2024-02-14 |
4 |
B |
$11.00 |
$22,000 |
D/D |
2,000 |
2,000 |
2.39 |
- |
|
| Celano Michael |
Chief Financial Officer |
• – – |
2024-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
31,250 |
143,996 |
|
- |
|
| Clayton Russell |
Chief Medical Officer |
• – – |
2024-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
22,500 |
22,500 |
|
- |
|
| Ben-Maimon Carole |
President and CEO |
• • – |
2024-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
66,125 |
332,954 |
|
- |
|
| Shankar Gopi |
Chief Development Officer |
• – – |
2024-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
22,500 |
27,500 |
|
- |
|
| Shankar Gopi |
Chief Development Officer |
• – – |
2023-12-07 |
4 |
B |
$3.73 |
$18,662 |
D/D |
5,000 |
5,000 |
2.74 |
- |
|
| Celano Michael |
Chief Financial Officer |
• – – |
2023-05-17 |
4 |
B |
$3.73 |
$18,632 |
D/D |
5,000 |
112,746 |
2.74 |
- |
|
| Truitt Joseph |
Director |
– • – |
2023-05-17 |
4 |
B |
$3.73 |
$10,258 |
D/D |
2,750 |
2,750 |
2.39 |
- |
|
| Ben-Maimon Carole |
President and CEO |
• • – |
2023-05-17 |
4 |
B |
$3.71 |
$18,525 |
D/D |
5,000 |
266,829 |
2.81 |
- |
|
| Ben-Maimon Carole |
President and CEO |
• • – |
2023-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
205,000 |
261,829 |
|
- |
|
| Celano Michael |
Chief Financial Officer |
• – – |
2023-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
76,000 |
107,746 |
|
- |
|
| Deerfield Capital Lp Et Al |
Director |
– • • |
2022-09-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,777,777 |
|
- |
|
| Hamilton Thomas Edward |
Director |
– • – |
2022-09-16 |
4 |
B |
$3.15 |
$999,999 |
D/D |
317,460 |
507,590 |
2.39 |
- |
|
| Deerfield Private Design Fund Iv, L.p. |
* Director by Deputization |
– • • |
2022-09-16 |
4 |
B |
$3.15 |
$34,999,990 |
I/I |
11,111,108 |
2,777,777 |
2.25 |
- |
|
| Ben-Maimon Carole |
President and CEO |
• • – |
2022-09-16 |
4 |
B |
$3.15 |
$100,000 |
D/D |
31,746 |
56,829 |
2.81 |
- |
|
| Celano Michael |
Chief Financial Officer |
• – – |
2022-09-16 |
4 |
B |
$3.15 |
$100,000 |
D/D |
31,746 |
31,746 |
2.74 |
- |
|
| Deerfield Private Design Fund Iv, L.p. |
* Director by Deputization |
– • • |
2021-06-30 |
4 |
B |
$8.75 |
$5,999,963 |
I/I |
685,710 |
1,943,420 |
2.25 |
- |
|
| Hamilton Thomas Edward |
Director |
– • – |
2021-06-30 |
4 |
B |
$8.75 |
$496,213 |
D/D |
56,710 |
190,130 |
2.39 |
- |
|
| Deerfield Healthcare Innovations Fund, L.p. |
Director |
– • • |
2020-05-28 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
6,091,250 |
|
- |
|
| Chondrial Therapeutics Holdings, Llc |
10% Owner |
– – • |
2020-05-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,091,250 |
|
- |
|
| Lamattina John L |
Director |
– • – |
2019-01-24 |
4 |
A |
$4.38 |
$47,497 |
D/D |
10,844 |
31,376 |
|
- |
|
| Perez Robert J |
Director |
– • – |
2019-01-24 |
4 |
A |
$4.38 |
$19,373 |
D/D |
4,423 |
5,322 |
|
- |
|
| Atlas Venture Associates Vii, Inc. |
10% Owner |
– – • |
2018-06-29 |
4 |
AS |
$0.00 |
$0 |
D/D |
(1,360,867) |
11 |
|
- |
|
| Hughes Thomas E. |
See Remarks |
• • – |
2018-06-28 |
4 |
AS |
$10.00 |
$320,000 |
D/D |
(32,000) |
125,247 |
|
- |
|
107 Records found
|
|
Page 1 of 5 |
|
|
